UBS lowered the firm’s price target on CVS Health (CVS) to $67 from $71 and keeps a Neutral rating on the shares. UBS says the firm is tempering its expectations for Q2, and feels that the reiteration of guidance is “good enough,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- ACA marketplace plans seek double digit rate increases for 2026, WSJ says
- U.S. Health insurers prescription drug denials on the rise, NYT says
- CVS Snatches CalPERS Pharmacy Contract from UnitedHealth
- Trump Trade: U.S. slaps 30% tariff rate on EU, Mexico
- Fight brewing over Medicare drug negotiation program, Bloomberg Law reports